Selcuk Seber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Selcuk Seber has a total of 267 co-authors. Here are the top co-authors by number of shared publications:
- Eyyüp Çavdar
Department of Medical Oncology, Faculty of Medicine, Tekirdağ Namık Kemal University, 59030 Tekirdağ, Türkiye
14 shared publications - Kubilay Karaboyun
Division of Medical Oncology, Department of Internal Medicine, Tekirdağ Namık Kemal University, Tekirdağ 59030, Turkey
13 shared publications - Okan Avcı
Tekirdag Namik Kemal University, Turkey
12 shared publications - Yakup İrIagac
Balıkesir Atatürk Şehir Hastanesi
9 shared publications - Meltem Öznur
Tekirdag Namik Kemal University, Turkey
8 shared publications F. Dane
7 shared publications
Latest Publications
- Open Access
- 23 April 2026
- Published by Adiyaman University in Adıyaman Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 12 (1) , 1-9
The role of surgery type in breast cancer patients with recurrent breast cancer receiving neoadjuvant chemotherapy
Aim: To assess the impact of surgical approach on recurrence and survival in breast cancer patients with recurrence post-neoadjuvant chemotherapy (NACT). Materials and Methods: A retrospective analysis included 108 female patients (≥18 years) who completed NACT (2010–2024) and developed recurrence. Patients underwent breast-conserving surgery (BCS) or mastectomy (MX), with sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). Recurrence-free survival (RFS), overall survival (OS), and associated factors were evaluated. Results: Among 108 patients (68 BCS, 40 MX, 18 SLNB, 90 ALND), the median RFS was 23.67 months (BCS: 24.53 vs. MX: 18.97; p=0.65; SLNB: 25.87 vs. ALND: 22.30; p=0.65). Five‑year RFS rates were 1% and 10% in the two groups, respectively. The median OS was 55.57 months (BCS: 56.07 vs. MX: 50.43; p=0.607; SLNB: 75.90 vs. ALND: 48.70; p=0.019). Molecular subtype (HR=2.12, p<0.001) and axillary surgery type (HR=4.41, p=0.005) were independent predictors of OS. The mean follow‑up duration was 59.96 ± 3.62 months. Conclusion: BCS and MX provide comparable RFS and OS in patients with recurrence after NACT. SLNB is associated with significantly improved OS compared with ALND, underscoring the importance of tailoring axillary management to tumor biology and patient-specific factors.
- 23 April 2026
- Published by Adiyaman University in Adıyaman Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 12 (1) , 1-9
Open AccessThe role of surgery type in breast cancer patients with recurrent breast cancer receiving neoadjuvant chemotherapy
Aim: To assess the impact of surgical approach on recurrence and survival in breast cancer patients with recurrence post-neoadjuvant chemotherapy (NACT). Materials and Methods: A retrospective analysis included 108 female patients (≥18 years) who completed NACT (2010–2024) and developed recurrence. Patients underwent breast-conserving surgery (BCS) or mastectomy (MX), with sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). Recurrence-free survival (RFS), overall survival (OS), and associated factors were evaluated. Results: Among 108 patients (68 BCS, 40 MX, 18 SLNB, 90 ALND), the median RFS was 23.67 months (BCS: 24.53 vs. MX: 18.97; p=0.65; SLNB: 25.87 vs. ALND: 22.30; p=0.65). Five‑year RFS rates were 1% and 10% in the two groups, respectively. The median OS was 55.57 months (BCS: 56.07 vs. MX: 50.43; p=0.607; SLNB: 75.90 vs. ALND: 48.70; p=0.019). Molecular subtype (HR=2.12, p<0.001) and axillary surgery type (HR=4.41, p=0.005) were independent predictors of OS. The mean follow‑up duration was 59.96 ± 3.62 months. Conclusion: BCS and MX provide comparable RFS and OS in patients with recurrence after NACT. SLNB is associated with significantly improved OS compared with ALND, underscoring the importance of tailoring axillary management to tumor biology and patient-specific factors.
- 19 February 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (4) , 1621-1629
Beyond the Patient: The Association Between Patient Functional Disability, Caregiver Burden, and Mental Health in Oncology
- 19 February 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (4) , 1621-1629
Beyond the Patient: The Association Between Patient Functional Disability, Caregiver Burden, and Mental Health in Oncology
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 72 (5) , e20252145
Independent prognostic ımpact of perineural ınvasion in breast cancer patients with residual disease after neoadjuvant chemotherapy
SUMMARY OBJECTIVE: Perineural invasion is a well-established adverse prognostic factor in several malignancies, yet its prognostic role in breast cancer remains controversial. METHODS: We retrospectively analyzed 400 breast cancer patients treated with neoadjuvant chemotherapy between 2012 and 2025 who had residual disease (non-pCR) at surgery. Clinicopathological variables, recurrence-free survival, and overall survival were evaluated using Cox proportional hazards models. RESULTS: Perineural invasion was identified in 42.5% of the cohort and associated with larger tumor burden, lymphovascular invasion, and nodal metastasis (p<0.01). Perineural invasion-positive status correlated with significantly inferior median recurrence-free survival (100.5 vs. 120.4 months; HR 1.77, p=0.008) and overall survival (108.5 vs. 133.6 months; HR 3.11, p<0.001). Multivariate analysis confirmed perineural invasion as a robust independent predictor of shorter recurrence-free survival and overall survival. The adverse impact was evident across all molecular subtypes, particularly HR+/HER2- and HER2+ groups. CONCLUSION: Perineural invasion is a strong independent prognostic factor for recurrence-free survival and overall survival in breast cancer patients with residual disease after neoadjuvant chemotherapy. Reporting perineural invasion status in routine pathology evaluations may aid in risk stratification for this high-risk population.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 72 (5) , e20252145
Open AccessIndependent prognostic ımpact of perineural ınvasion in breast cancer patients with residual disease after neoadjuvant chemotherapy
SUMMARY OBJECTIVE: Perineural invasion is a well-established adverse prognostic factor in several malignancies, yet its prognostic role in breast cancer remains controversial. METHODS: We retrospectively analyzed 400 breast cancer patients treated with neoadjuvant chemotherapy between 2012 and 2025 who had residual disease (non-pCR) at surgery. Clinicopathological variables, recurrence-free survival, and overall survival were evaluated using Cox proportional hazards models. RESULTS: Perineural invasion was identified in 42.5% of the cohort and associated with larger tumor burden, lymphovascular invasion, and nodal metastasis (p<0.01). Perineural invasion-positive status correlated with significantly inferior median recurrence-free survival (100.5 vs. 120.4 months; HR 1.77, p=0.008) and overall survival (108.5 vs. 133.6 months; HR 3.11, p<0.001). Multivariate analysis confirmed perineural invasion as a robust independent predictor of shorter recurrence-free survival and overall survival. The adverse impact was evident across all molecular subtypes, particularly HR+/HER2- and HER2+ groups. CONCLUSION: Perineural invasion is a strong independent prognostic factor for recurrence-free survival and overall survival in breast cancer patients with residual disease after neoadjuvant chemotherapy. Reporting perineural invasion status in routine pathology evaluations may aid in risk stratification for this high-risk population.
- Open Access
- 26 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (39) , e44743
The role of peripheral T lymphocyte subsets and PD-1 expression as a biomarker for neoadjuvant treatment response in breast cancer
Background: The prognostic and predictive role of the interaction of the immune system with the tumor during the disease process has become increasingly important in recent years. T lymphocyte subgroups in peripheral blood can be used to monitor this dynamic interaction. We evaluated the relationship between baseline peripheral T lymphocyte subsets and treatment response (best objective response) in 47 breast cancer patients receiving neoadjuvant chemotherapy. Methods: This study investigated the impact of initial peripheral T lymphocyte subsets on neoadjuvant chemotherapy response in patients with invasive ductal breast. A total of 47 consecutive patients whose peripheral blood samples were able was included in the study group. The patients’ T lymphocyte subsets were measured before treatment. The patients were then followed up to assess their treatment response. Results: In our study, we found a significant negative relationship between baseline CD3, CD4, and CD8 absolute counts and pathologic complete response. We also found that high CD4/programmed cell death protein 1 expression (OR: 0.212, 95% CI: 0.061–0.735, P = .015) and high CD8/programmed cell death protein 1 expression (OR: 0.250, 95% CI: 0.073–0.858, P = .028) from baseline peripheral T lymphocyte were correlated with poor pathologic complete response. Conclusions: These results suggest that T lymphocyte subsets may be a predictive biomarker for treatment response in patients with breast cancer undergoing neoadjuvant chemotherapy. Further studies are needed to confirm these findings and to identify the optimal T lymphocyte subset for predicting treatment response.
- 26 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (39) , e44743
Open AccessThe role of peripheral T lymphocyte subsets and PD-1 expression as a biomarker for neoadjuvant treatment response in breast cancer
Background: The prognostic and predictive role of the interaction of the immune system with the tumor during the disease process has become increasingly important in recent years. T lymphocyte subgroups in peripheral blood can be used to monitor this dynamic interaction. We evaluated the relationship between baseline peripheral T lymphocyte subsets and treatment response (best objective response) in 47 breast cancer patients receiving neoadjuvant chemotherapy. Methods: This study investigated the impact of initial peripheral T lymphocyte subsets on neoadjuvant chemotherapy response in patients with invasive ductal breast. A total of 47 consecutive patients whose peripheral blood samples were able was included in the study group. The patients’ T lymphocyte subsets were measured before treatment. The patients were then followed up to assess their treatment response. Results: In our study, we found a significant negative relationship between baseline CD3, CD4, and CD8 absolute counts and pathologic complete response. We also found that high CD4/programmed cell death protein 1 expression (OR: 0.212, 95% CI: 0.061–0.735, P = .015) and high CD8/programmed cell death protein 1 expression (OR: 0.250, 95% CI: 0.073–0.858, P = .028) from baseline peripheral T lymphocyte were correlated with poor pathologic complete response. Conclusions: These results suggest that T lymphocyte subsets may be a predictive biomarker for treatment response in patients with breast cancer undergoing neoadjuvant chemotherapy. Further studies are needed to confirm these findings and to identify the optimal T lymphocyte subset for predicting treatment response.
- Open Access
- 25 June 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 126 (10) , 2721-2727
Prognostic Value of Estrogen Receptor Co-activator AIB1 in Metastatic Breast Cancer Patients Treated with a Combination of Ribociclib and Letrozole
Purpose: The steroid receptor co-activator protein family members are transcriptional regulators that interact with steroid receptors, mainly estrogen receptors. We assessed the prognostic role of SRC-3, AIB1, in metastatic breast cancer patients treated with ribociclib and letrozole in combination therapy. Methods: Forty-two patients were included in this retrospective study. AIB1 level was determined by immunohistochemical methods. The AIB1 expression score was calculated as the sum of a proportion score and an intensity score, representing the estimated proportion of stained cell nuclei. Results: The median PFS (mPFS) of all patients was 22.4 months. Univariate cox regression analysis was performed to identify prognostic factors. Low AIB1 expression score (HR = 0.33, 95% CI 0.12–0.96, p = 0.042), low ER level (HR = 0.97, 95% CI 0.95–0.99, p = 0.001) and presence of liver metastasis (HR = 5.30, 95% CI 2.14–13.13, p < 0.001) were found to be poor prognostic factors. A statistically significant correlation was found between AIB1 expression score and prior chemotherapy, prior hormonotherapy, presence of bone metastasis, liver metastasis and PgR level (p = 0.08, p = 0.018, p = 0.041, p = 0.040, and p = 0.007, respectively). Conclusions: We believe that the AIB1 score, which was investigated for the first time in this study and whose prognostic features have been presented, may be a guide in identifying high-risk patients requiring close follow-up in patients receiving the combination of ribociclib and letrozole and in investigating further targeted therapies.
- 25 June 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 126 (10) , 2721-2727
Open AccessPrognostic Value of Estrogen Receptor Co-activator AIB1 in Metastatic Breast Cancer Patients Treated with a Combination of Ribociclib and Letrozole
Purpose: The steroid receptor co-activator protein family members are transcriptional regulators that interact with steroid receptors, mainly estrogen receptors. We assessed the prognostic role of SRC-3, AIB1, in metastatic breast cancer patients treated with ribociclib and letrozole in combination therapy. Methods: Forty-two patients were included in this retrospective study. AIB1 level was determined by immunohistochemical methods. The AIB1 expression score was calculated as the sum of a proportion score and an intensity score, representing the estimated proportion of stained cell nuclei. Results: The median PFS (mPFS) of all patients was 22.4 months. Univariate cox regression analysis was performed to identify prognostic factors. Low AIB1 expression score (HR = 0.33, 95% CI 0.12–0.96, p = 0.042), low ER level (HR = 0.97, 95% CI 0.95–0.99, p = 0.001) and presence of liver metastasis (HR = 5.30, 95% CI 2.14–13.13, p < 0.001) were found to be poor prognostic factors. A statistically significant correlation was found between AIB1 expression score and prior chemotherapy, prior hormonotherapy, presence of bone metastasis, liver metastasis and PgR level (p = 0.08, p = 0.018, p = 0.041, p = 0.040, and p = 0.007, respectively). Conclusions: We believe that the AIB1 score, which was investigated for the first time in this study and whose prognostic features have been presented, may be a guide in identifying high-risk patients requiring close follow-up in patients receiving the combination of ribociclib and letrozole and in investigating further targeted therapies.
- Open Access
- 25 March 2025
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
- Vol. 16 (1) , 123-130
Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study
Aim: Muscle-invasive bladder cancer requires systemic treatment due to its high risk of metastasis. However, studies comparing neoadjuvant and adjuvant therapy regimens are currently limited. Our goal in this study was to compare the treatment efficacy of patients receiving neoadjuvant or adjuvant treatment in locally advanced bladder cancer. Material and Methods: We retrospectively included 107 bladder cancer patients from 6 centres who underwent radical cystectomy and received perioperative chemotherapy. Patients were divided into 2 categories: (i) neoadjuvant chemotherapy (n=54) and (ii) adjuvant chemotherapy (n=53). Results: Median follow-up was 31.6 months (95%CI 21.8-41.4). 30-month disease-free survival (DFS) was 58.9% in the whole group, 56.3% in neoadjuvant and 61.5% in adjuvant. 30-month DFS after neoadjuvant treatment was 70.1% in
- 25 March 2025
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
- Vol. 16 (1) , 123-130
Open AccessEffects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study
Aim: Muscle-invasive bladder cancer requires systemic treatment due to its high risk of metastasis. However, studies comparing neoadjuvant and adjuvant therapy regimens are currently limited. Our goal in this study was to compare the treatment efficacy of patients receiving neoadjuvant or adjuvant treatment in locally advanced bladder cancer. Material and Methods: We retrospectively included 107 bladder cancer patients from 6 centres who underwent radical cystectomy and received perioperative chemotherapy. Patients were divided into 2 categories: (i) neoadjuvant chemotherapy (n=54) and (ii) adjuvant chemotherapy (n=53). Results: Median follow-up was 31.6 months (95%CI 21.8-41.4). 30-month disease-free survival (DFS) was 58.9% in the whole group, 56.3% in neoadjuvant and 61.5% in adjuvant. 30-month DFS after neoadjuvant treatment was 70.1% in
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 71 (9) , e20250507
Expression of gamma-aminobutyric acid type A receptor subunit π and minichromosome maintenance-3 in breast cancer patients treated with neoadjuvant chemotherapy: a target molecule or a proliferation marker?
SUMMARY OBJECTIVE: The receptors and cell membrane channels found in breast cancer in high numbers have been promising for drugs in the past and in the future. In addition, analyses of proliferation indices play an essential role in predicting the success of these treatments. METHODS: Gamma-aminobutyric acid type A receptor subunit π and minichromosome maintenance-3 expressions were studied by immunohistochemical staining from tissue samples obtained by trucut biopsy from epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy. RESULTS: The study included 101 patients. Almost 96.0% of the breast tumor tissues expressed gamma-aminobutyric acid type A receptor subunit π. The median value for gamma-aminobutyric acid type A receptor subunit π was calculated as 30% (19 patients) and the median for minichromosome maintenance-3 as 80% (13 patients). When neoadjuvant chemotherapy response was evaluated, pathological complete response was achieved in 23.8% of patients (n=24). Pathological complete response was achieved in 16.4% of patients for hormone receptor positivity and in 38.2% of patients for triple-negative breast cancer. When the factors predicting pathological complete response were evaluated with univariate analysis, age (p=0.044), molecular subtype (p=0.017), menopausal status (p=0.032), Ki-67 increase (p<0.001), estrogen receptor decrease (p<0.006), progesterone receptor decrease (p<0.002), and grade (p<0.001) predicted treatment response. There was no relationship between gamma-aminobutyric acid type A receptor subunit π (p=0.945) and minichromosome maintenance-3 (p=0.985) and treatment response. CONCLUSION: Our study found that gamma-aminobutyric acid type A receptor subunit π is highly expressed in breast cancer cells but absent in normal breast tissue, making it a potential therapeutic target. Additionally, we determined that minichromosome maintenance-3 is not a reliable proliferation index or predictor of treatment response.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 71 (9) , e20250507
Open AccessExpression of gamma-aminobutyric acid type A receptor subunit π and minichromosome maintenance-3 in breast cancer patients treated with neoadjuvant chemotherapy: a target molecule or a proliferation marker?
SUMMARY OBJECTIVE: The receptors and cell membrane channels found in breast cancer in high numbers have been promising for drugs in the past and in the future. In addition, analyses of proliferation indices play an essential role in predicting the success of these treatments. METHODS: Gamma-aminobutyric acid type A receptor subunit π and minichromosome maintenance-3 expressions were studied by immunohistochemical staining from tissue samples obtained by trucut biopsy from epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy. RESULTS: The study included 101 patients. Almost 96.0% of the breast tumor tissues expressed gamma-aminobutyric acid type A receptor subunit π. The median value for gamma-aminobutyric acid type A receptor subunit π was calculated as 30% (19 patients) and the median for minichromosome maintenance-3 as 80% (13 patients). When neoadjuvant chemotherapy response was evaluated, pathological complete response was achieved in 23.8% of patients (n=24). Pathological complete response was achieved in 16.4% of patients for hormone receptor positivity and in 38.2% of patients for triple-negative breast cancer. When the factors predicting pathological complete response were evaluated with univariate analysis, age (p=0.044), molecular subtype (p=0.017), menopausal status (p=0.032), Ki-67 increase (p<0.001), estrogen receptor decrease (p<0.006), progesterone receptor decrease (p<0.002), and grade (p<0.001) predicted treatment response. There was no relationship between gamma-aminobutyric acid type A receptor subunit π (p=0.945) and minichromosome maintenance-3 (p=0.985) and treatment response. CONCLUSION: Our study found that gamma-aminobutyric acid type A receptor subunit π is highly expressed in breast cancer cells but absent in normal breast tissue, making it a potential therapeutic target. Additionally, we determined that minichromosome maintenance-3 is not a reliable proliferation index or predictor of treatment response.
- 30 November 2023
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 24 (4) , 334-339
The Role of Interleukin-20 in Paclitaxel-Associated Peripheral Neuropathy in Non-Metastatic Breast Cancer Patients Receiving Chemotherapy
- 30 November 2023
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 24 (4) , 334-339
The Role of Interleukin-20 in Paclitaxel-Associated Peripheral Neuropathy in Non-Metastatic Breast Cancer Patients Receiving Chemotherapy
- Open Access
- 31 August 2023
- Published by Hatay Mustafa Kemal University Faculty of Medicine in Interdisciplinary Medical Journal
- Vol. 14 (49) , 100-104
The prognostic role of neutrophil/lymphocyte ratio and monocyte/lymphocyte ratio in advanced stage gastric cancer patients receiving chemotherapy: a single center experience
Objective: Several studies revealed that peripheral blood Neutrophil/Lymphocyte ratio (NLR) and Monocyte/Lymphocyte Ratio (MLR) were prognostic in various cancer types. However, there are no excessive information about the prognostic significance of NLR and MLR in patients with advanced gastric cancer. As a result, we examined whether NLR and/or MLR could be used as a prognostic marker to predict survival outcomes in patients with advanced gastric cancer receiving palliative chemotherapy. Method: We retrospectively analyzed 119 patients with gastric cancer receiving chemotherapy. We evaluated the relationship between potential prognostic factors and overall survival (OS) times using the Kaplan-Meier method and Cox regression survival modelling. Results: The median overall survival of the patients was 6.9 (2.1-41.6) months. In univariate analysis, NLR (p< 0.001), ECOG performance status (p< 0.001), presence of liver metastases (p< 0.001) and presence of peritoneal metastases (p< 0.001) were found to be associated with survival. The multivariate survival model showed the high NLR (HR=1.59, 95% CI 1.6-2.40, p= 0.026), the patients with ECOG performance score 2-3 (HR=2.91, 95% CI 1.60-5.27, p<0.001), the presence of liver metastasis (HR=2.10, 95% CI 1.35-3.21, p=0.001) and the presence of peritoneal metastases (HR=2.68, 95% CI 1.72-4.17, p<0.001) as independent predictors of survival. Conclusion: Pretreatment high NLR, ECOG performance status, and presence of liver or peritoneal metastases are powerful prognostic factors in advanced gastric cancer patients. These prognostic factors, which are easily accessible in clinical practice, can be used as helpful tools for clinicians in the management of the disease.
- 31 August 2023
- Published by Hatay Mustafa Kemal University Faculty of Medicine in Interdisciplinary Medical Journal
- Vol. 14 (49) , 100-104
Open AccessThe prognostic role of neutrophil/lymphocyte ratio and monocyte/lymphocyte ratio in advanced stage gastric cancer patients receiving chemotherapy: a single center experience
Objective: Several studies revealed that peripheral blood Neutrophil/Lymphocyte ratio (NLR) and Monocyte/Lymphocyte Ratio (MLR) were prognostic in various cancer types. However, there are no excessive information about the prognostic significance of NLR and MLR in patients with advanced gastric cancer. As a result, we examined whether NLR and/or MLR could be used as a prognostic marker to predict survival outcomes in patients with advanced gastric cancer receiving palliative chemotherapy. Method: We retrospectively analyzed 119 patients with gastric cancer receiving chemotherapy. We evaluated the relationship between potential prognostic factors and overall survival (OS) times using the Kaplan-Meier method and Cox regression survival modelling. Results: The median overall survival of the patients was 6.9 (2.1-41.6) months. In univariate analysis, NLR (p< 0.001), ECOG performance status (p< 0.001), presence of liver metastases (p< 0.001) and presence of peritoneal metastases (p< 0.001) were found to be associated with survival. The multivariate survival model showed the high NLR (HR=1.59, 95% CI 1.6-2.40, p= 0.026), the patients with ECOG performance score 2-3 (HR=2.91, 95% CI 1.60-5.27, p<0.001), the presence of liver metastasis (HR=2.10, 95% CI 1.35-3.21, p=0.001) and the presence of peritoneal metastases (HR=2.68, 95% CI 1.72-4.17, p<0.001) as independent predictors of survival. Conclusion: Pretreatment high NLR, ECOG performance status, and presence of liver or peritoneal metastases are powerful prognostic factors in advanced gastric cancer patients. These prognostic factors, which are easily accessible in clinical practice, can be used as helpful tools for clinicians in the management of the disease.
- 10 May 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (6) , 1-8
Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?
Aim The primary aim of this study was to compare tamoxifen versus aromatase inhibitors (AI) in terms of urinary incontinence (UI) in premenopausal female patients receiving adjuvant hormone therapy for breast cancer. A secondary aim was to investigate the prevalence and the affecting factors of UI. Methods This study was designed as a multicenter, cross-sectional that included consecutive premenopausal breast cancer patients ≤50 years of age receiving tamoxifen (with/without LHRHa) or AI (with LHRHa) for at least 6 months, between June 2021 and September 2022. Patients with urinary incontinence before hormone treatments and metastatic patients were excluded from the study. Turkish validation of The International Consultation on Incontinence Modular Questionnaire Urinary Incontinence Short Form (ICIQ UI-SF) was used to determine the UI. Using logistic regression methods, we analyzed potential predictive factors for UI. Results A total of 206 breast cancer patients were included in this study. A total of 120 (58.2%) patients were receiving tamoxifen plus LHRHa, 40 (19.4%) patients were receiving aromatase inhibitor plus LHRHa, and 46 (22.3%) patients were receiving tamoxifen only. In this study, the prevalence of urinary incontinence was found to be 35.9% (n:74). 41% of the patients receiving tamoxifen and 15.0% of those receiving aromatase inhibitors had complaints of urinary incontinence. There was a statistically significant difference between patients receiving tamoxifen or aromatase inhibitor in terms of urinary incontinence (p=0.001). In the univariate analysis established to predict UI, parity (≥2 vs p= 0.001), tamoxifen (vs AI) (OR = 3.97, 95% CI: 1.58–9.98, p= 0.003), age ( ≥40 vs. p= 0.005), vaginal deliveries (≥2 vs. p= 0.005), hypertension (OR = 3.59, 95% CI: 1.43–9.02, p= 0.007), diuretic use (OR = 2.55, 95% CI: 1.09–5.95, p= 0.031) ), and body mass index (≥25 vs p= 0.034) was found to be predictive. Tamoxifen (OR = 4.71, 95% CI: 1.77–12.56, p= 0.002), hypertension (OR = 3.48, 95% CI: 1.27–9.52, p= 0.015), and age (OR = 2.35, 95% CI: 1.10–5.02, p= 0.027) remained independent predictors for incontinence in multivariate analyses. Conclusion We found that tamoxifen had increased the risk of urinary incontinence compared to aromatase inhibitors in patients receiving hormone therapy for breast cancer. In addition, we showed that age and hypertension were also independent predictors for UI. In the context of quality of life, we recommend close follow-up of these patients, as drug adherence may be affected in the event of urinary incontinence.
- 10 May 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (6) , 1-8
Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?
Aim The primary aim of this study was to compare tamoxifen versus aromatase inhibitors (AI) in terms of urinary incontinence (UI) in premenopausal female patients receiving adjuvant hormone therapy for breast cancer. A secondary aim was to investigate the prevalence and the affecting factors of UI. Methods This study was designed as a multicenter, cross-sectional that included consecutive premenopausal breast cancer patients ≤50 years of age receiving tamoxifen (with/without LHRHa) or AI (with LHRHa) for at least 6 months, between June 2021 and September 2022. Patients with urinary incontinence before hormone treatments and metastatic patients were excluded from the study. Turkish validation of The International Consultation on Incontinence Modular Questionnaire Urinary Incontinence Short Form (ICIQ UI-SF) was used to determine the UI. Using logistic regression methods, we analyzed potential predictive factors for UI. Results A total of 206 breast cancer patients were included in this study. A total of 120 (58.2%) patients were receiving tamoxifen plus LHRHa, 40 (19.4%) patients were receiving aromatase inhibitor plus LHRHa, and 46 (22.3%) patients were receiving tamoxifen only. In this study, the prevalence of urinary incontinence was found to be 35.9% (n:74). 41% of the patients receiving tamoxifen and 15.0% of those receiving aromatase inhibitors had complaints of urinary incontinence. There was a statistically significant difference between patients receiving tamoxifen or aromatase inhibitor in terms of urinary incontinence (p=0.001). In the univariate analysis established to predict UI, parity (≥2 vs p= 0.001), tamoxifen (vs AI) (OR = 3.97, 95% CI: 1.58–9.98, p= 0.003), age ( ≥40 vs. p= 0.005), vaginal deliveries (≥2 vs. p= 0.005), hypertension (OR = 3.59, 95% CI: 1.43–9.02, p= 0.007), diuretic use (OR = 2.55, 95% CI: 1.09–5.95, p= 0.031) ), and body mass index (≥25 vs p= 0.034) was found to be predictive. Tamoxifen (OR = 4.71, 95% CI: 1.77–12.56, p= 0.002), hypertension (OR = 3.48, 95% CI: 1.27–9.52, p= 0.015), and age (OR = 2.35, 95% CI: 1.10–5.02, p= 0.027) remained independent predictors for incontinence in multivariate analyses. Conclusion We found that tamoxifen had increased the risk of urinary incontinence compared to aromatase inhibitors in patients receiving hormone therapy for breast cancer. In addition, we showed that age and hypertension were also independent predictors for UI. In the context of quality of life, we recommend close follow-up of these patients, as drug adherence may be affected in the event of urinary incontinence.